YANKCOM Partnership Invests $92,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

YANKCOM Partnership bought a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 501 shares of the medical research company’s stock, valued at approximately $92,000.

A number of other hedge funds also recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. raised its stake in Charles River Laboratories International by 46.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company’s stock valued at $987,000 after acquiring an additional 1,679 shares during the period. E. Ohman J or Asset Management AB raised its stake in Charles River Laboratories International by 225.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company’s stock valued at $480,000 after acquiring an additional 1,800 shares during the period. Trust Point Inc. bought a new stake in Charles River Laboratories International in the 4th quarter valued at about $378,000. Boston Trust Walden Corp raised its stake in Charles River Laboratories International by 4.3% in the 4th quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company’s stock valued at $37,748,000 after acquiring an additional 8,338 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. raised its stake in Charles River Laboratories International by 24.5% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,463 shares of the medical research company’s stock valued at $455,000 after acquiring an additional 485 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. JPMorgan Chase & Co. lowered their price objective on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Monday. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. Evercore ISI upped their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. UBS Group reiterated a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, Bank of America decreased their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and a consensus price target of $200.79.

Charles River Laboratories International Stock Up 0.3 %

Shares of NYSE CRL opened at $166.32 on Friday. Charles River Laboratories International, Inc. has a 12 month low of $159.65 and a 12 month high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $8.51 billion, a price-to-earnings ratio of 20.82, a PEG ratio of 6.25 and a beta of 1.37. The business has a 50-day moving average of $181.32 and a 200-day moving average of $194.07.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.72 earnings per share. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.17 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).